Trial Profile

Phase 1, first-in-human, clinical study to evaluate the safety profile, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LIFE-001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LIFE 001 (Primary)
Indications Immunological disorders; Transplant rejection; Ulcerative colitis
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

15 Apr 2025 New trial record
08 Apr 2025 According to LifeMine Therapeutics media release, first participant has been dosed in this trial
08 Apr 2025 According to LifeMine Therapeutics media release, LifeMine, supported by a committed syndicate of top-tier investors, has secured funding for the entire Phase 1a study, and is currently bringing in additional capital to power efficacy studies and provide additional investment catalysts in 2026 and beyond.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com